Nyxoah (NYXH BR) stock market data APIs
€2.7023
-0.08(-3%)
as of March 23, 2026
Try our APIs with
free plan!
Nyxoah Financial Data Overview
Price chart is built with
Anychart
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Prev. Close
2.7023
Open
2.6206
High
2.7151
Low
2.4851
52 wk Range
2.5-10.75
Market Cap
119 M
Shares Outstanding
43 662 K
Revenue
5 639 K
EPS
-0.59
Beta
0.62
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nyxoah data using free add-ons & libraries
Get Nyxoah Fundamental Data
Nyxoah Fundamental data includes:
- Net Revenue: 5 639 K
- EBITDA: -82 152 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: -0.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nyxoah News
New
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are...
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Nyxoah SA (NYXH) reports results for the quarter ended September 2025. While this widely-known consensus outlook is imp...
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Nyxoah NYXH has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first comme...
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
Last week, Nyxoah SA NYXH announced the continued expansion of its commercial footprint in the Middle East. This follows the company's first successful Genio implant in Abu Dhabi in September 2025. I...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
